Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.34 |
| ▸ | KDR | P35968 | 7/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TRPM5 | Q9NZQ8 | 2/20 | 0.34 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126277 | 0.93 | KDM4E (0.36) | TSHRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4074571 | 0.82 | MEN1 (0.43) | MEN1KMT2ATSHRFGFR1FGFR2 | |
| SCHEMBL4068129 | 0.82 | KDM4E (0.36) | TSHRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL2125726 | 0.80 | MEN1 (0.37) | MEN1KMT2ATSHROPRK1FGFR1 | |
| SCHEMBL1797127 | 0.79 | OPRK1 (0.45) | MEN1KMT2ATSHRFDPSOPRK1 | |
| SCHEMBL8142536 | 0.77 | TSHR (0.48) | KMT2ATSHRFGFR1FGFR2FGFR4 | |
| SCHEMBL16125136 | 0.75 | KDM4E (0.37) | TSHRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4215152 | 0.75 | SORD (0.42) | TSHRFDPSFGFR1FGFR2FGFR4 | |
| SCHEMBL4200809 | 0.75 | KDM4E (0.37) | TSHRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL20309635 | 0.75 | KDM4E (0.37) | TSHRFGFR1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519124-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-1961744-B1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8168783-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1961744-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | CXCR4, CXCL12, CXCR3 | MEN1 1493/4885KMT2A 3189/4885TSHR 1616/4885 |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR3, CXCR1 | MEN1 2594/4885KMT2A 3359/4885TSHR 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.